Ipratropium bromide treatment of experimental rhinovirus infection.

摘要: The importance of parasympathetic-cholinergic mechanisms in the production common cold symptoms is not clear. quaternary ammonium anticholinergic antagonist ipratropium bromide was intranasally administered under double-blind, randomized, placebo-controlled conditions to assess its tolerance and efficacy reducing nasal hypersecretion adult volunteers with experimental rhinovirus colds. Ipratropium sprayed three times daily (80 micrograms per treatment) for 5 days beginning 24 h after intranasal inoculation type 39. Clinical colds occurred 50% 30 infected recipients 76% 33 placebo (P = 0.04). mucus weights tended be lower ipratropium-treated persons (mean +/- standard deviation, 14.7 15.1 g/5 days) than placebo-treated (24.7 28.0 days; P 0.076). Whereas total symptom scores were similar between two groups, rhinorrhea score analyzed each day treatment showed nonsignificant trends favoring group over last 4 treatment. generally well tolerated. results suggest that cholinergic are at least partially responsible but effect compounds alone insufficient practical use treatment, although they may have value as components multi-ingredient preparations.